Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.37 |
| ▸ | PPARG | P37231 | 7/20 | 0.37 |
| ▸ | PPARD | Q03181 | 7/20 | 0.37 |
| ▸ | PPARA | Q07869 | 7/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | FABP4 | P15090 | 2/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31053791 | 0.95 | TSHR (0.47) | TSHRAKR1B1GPR84PPARGPPARD | |
| SCHEMBL31386976 | 0.83 | ALDH1A1 (0.43) | TSHRALDH1A1 | |
| SCHEMBL27387114 | 0.79 | TSHR (0.56) | TSHRAKR1B1GPR84PPARGPPARD | |
| SCHEMBL31537920 | 0.75 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL31039401 | 0.74 | PTPN7 (0.51) | PPARGPPARAALDH1A1TDP1KMT2A | |
| SCHEMBL1848455 | 0.73 | ALDH1A1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL1595383 | 0.73 | TSHR (0.44) | TSHRGPR84PPARGPPARDPPARA | |
| SCHEMBL8624294 | 0.72 | TSHR (0.31) | TSHR | |
| SCHEMBL4921825 | 0.71 | HPGD (0.34) | — | |
| Butane SCHEMBL4186449 | 0.70 | TSHR (0.60) | TSHRAKR1B1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178890-A1 | PURIFICATION OF ROSUVASTATIN INTERMEDIATE BY THIN FILM EVAPORATION AND CHEMICAL METHOD | Teva Pharmaceutical Industries Ltd. (IL) | 2010-04-28 | — | — | EP | claimed |
| JP-2010501643-A | — | — | 2010-01-21 | — | — | JP | claimed |
| WO-2009009153-A9 | PURIFICATION OF ROSUVASTATIN INTERMEDIATE BY THIN FILM EVAPORATION AND CHEMICAL METHOD | TEVA PHARMA (IL) | 2009-06-18 | — | — | WO | claimed |
| WO-2009009153-A1 | PURIFICATION OF ROSUVASTATIN INTERMEDIATE BY THIN FILM EVAPORATION AND CHEMICAL METHOD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-01-15 | — | — | WO | claimed |
| US-7884226-B2 | combining a formulation containing t-butyl (3R)-3-(t-butyldimethylsilyloxy)-6-dimethoxyphosphinyl-5-oxohexanoate (19TBPO) with basic and/or oxidizing agents ( NaOH, Potassium permanganate), extracting the 19TBPO into a water immiscible organic solvent | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2011-02-08 | — | — | US | disclosed |
| EP-2178890-A1 | PURIFICATION OF ROSUVASTATIN INTERMEDIATE BY THIN FILM EVAPORATION AND CHEMICAL METHOD | Teva Pharmaceutical Industries Ltd. (IL) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009009153-A9 | PURIFICATION OF ROSUVASTATIN INTERMEDIATE BY THIN FILM EVAPORATION AND CHEMICAL METHOD | TEVA PHARMA (IL) | 2009-06-18 | — | — | WO | disclosed |
| US-20090099383-A1 | Purification of rosuvatatin intermediate by thin film evaporation and chemical method | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-04-16 | — | — | US | disclosed |
| WO-2009009153-A1 | PURIFICATION OF ROSUVASTATIN INTERMEDIATE BY THIN FILM EVAPORATION AND CHEMICAL METHOD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099383-A1 | Purification of rosuvatatin intermediate by thin film evaporation and chemical method | HMGCR, HDLBP, CETP | TSHR 4132/4885AKR1B1 2286/4885GPR84 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.